المؤلفون: Ezoe, Yasumasa, Mizusawa, Junki, Katayama, Hiroshi, Kataoka, Kozo, Muto, Manabu

المساهمون: 武藤, 学, 40360698

مصطلحات موضوعية: hyponatremia, platinum agent, cisplatin, carboplatin, risk factors

الوصف: Background: Hyponatremia is a common electrolyte abnormality in cancer patients who receive chemotherapy. Among anticancer agents, platinum-based agents are reported to cause chemotherapy-induced hyponatremia. However, the actual incidence and risk factors remain unknown. Results: The reports of 29 trials were analyzed. The incidence of grade 3/4 hyponatremia was 11.9% in patients treated with platinum-based chemotherapy and 3.8% in those treated with nonplatinum-based regimens (P < 0.01). Univariable analysis revealed a high incidence of hyponatremia in patients receiving cisplatin, three-drug combination regimen, two-drug combination regimen with amrubicin or irinotecan, or high-dose cisplatin (weekly equivalent cisplatin dose ≥20 mg/m²), and in patients with small-cell lung cancer. Conclusion: This is the first report of the actual incidence and the potential risk factors of chemotherapy-induced hyponatremia. Careful monitoring of serum sodium level is needed when platinum-based chemotherapy is administered. Methods: This study included all clinical trials of systemic chemotherapies for solid cancers that were conducted by the Japan Clinical Oncology Group (JCOG) after January 2000 and of which the patient enrolment was completed by January 2014. The latest reports of each trial were used for analysis. The incidence of chemotherapy-induced grade 3/4 hyponatremia and the potential risk factors were investigated with univariable analysis.

وصف الملف: application/pdf

العلاقة: http://hdl.handle.net/2433/255285Test; Oncotarget; 6595; 6606

الإتاحة: http://hdl.handle.net/2433/255285Test

المؤلفون: Terashima, Masanori, Iwasaki, Yoshiaki, Mizusawa, Junki, Katayama, Hiroshi, Nakamura, Kenichi, Katai, Hitoshi, Yoshikawa, Takaki, Ito, Yuichi, Kaji, Masahide, Kimura, Yutaka, Hirao, Motohiro, Yamada, Makoto, Kurita, Akira, Takagi, Masakazu, Boku, Narikazu, Sano, Takeshi, Sasako, Mitsuru

المصدر: Gastric Cancer; Sep2019, Vol. 22 Issue 5, p1044-1052, 9p

مصطلحات موضوعية: STOMACH cancer, CLINICAL trial registries, CISPLATIN, ADJUVANT treatment of cancer, ONCOLOGY

مستخلص: Background: The prognosis of patients with linitis plastica (type 4) and large (≥ 8 cm) ulcero-invasive-type (type 3) gastric cancer is extremely poor, even after extended surgery and adjuvant chemotherapy. Given the promising results of our previous phase II study evaluating neoadjuvant chemotherapy (NAC) with S-1 plus cisplatin (JCOG0210), we performed a phase III study to confirm the efficacy of NAC in these patients, with the safety and surgical results are presented here. Methods: Eligible patients were randomized to gastrectomy plus adjuvant chemotherapy with S-1 (Arm A) or NAC followed by gastrectomy + adjuvant chemotherapy (Arm B). The primary endpoint was the overall survival (OS). This trial is registered at the UMIN Clinical Trials Registry as C000000279. Results: From February 2007 to July 2013, 300 patients were randomized (Arm A 149, Arm B 151). NAC was completed in 133 patients (88%). Major grade 3/4 adverse events during NAC were neutropenia (29.3%), nausea (5.4%), diarrhea (4.8%), and fatigue (2.7%). Gastrectomy was performed in 147 patients (99%) in Arm A and 139 patients (92%) in Arm B. The operation time was significantly shorter in Arm B than in Arm A (median 255 vs. 240 min, respectively; p = 0.024). There were no significant differences in Grade 2–4 morbidity and mortality (25.2% and 1.3% in Arm A and 15.8% and 0.7% in Arm B, respectively). Conclusions: NAC for type 4 and large type 3 gastric cancer followed by D2 gastrectomy can be safely performed without increasing the morbidity or mortality. [ABSTRACT FROM AUTHOR]

: Copyright of Gastric Cancer is the property of Springer Nature and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)

المؤلفون: Ito, Seiji, Nashimoto, Atsushi, Nakamori, Mikihito, Onaya, Hiroaki, Sasako, Mitsuru, Sano, Takeshi, Mizusawa, Junki, Takahari, Daisuke, Katayama, Hiroshi, Katai, Hitoshi, Kawashima, Yoshiyuki, Kinoshita, Takahiro, Terashima, Masanori

المصدر: Gastric Cancer; Mar2017, Vol. 20 Issue 2, p322-331, 10p

مصطلحات موضوعية: LYMPH nodes, GASTROINTESTINAL cancer, DOCETAXEL, CISPLATIN, PREOPERATIVE care

مستخلص: Background: Gastric cancer with extensive lymph node metastasis is commonly considered unresectable, with a poor prognosis. We previously reported the results of the use of cisplatin and S-1 as preoperative chemotherapy for gastric cancer with extensive lymph node metastasis; docetaxel, cisplatin, and S-1 (DCS) have now been investigated for the same purpose. Methods: Patients received two or three 28-day cycles of DCS therapy (docetaxel at 40 mg/m and cisplatin at 60 mg/m on day 1, S-1 at 40 mg/m twice daily for 2 weeks) followed by gastrectomy with D2 plus para-aortic nodal dissection. After R0 resection, S-1 chemotherapy was given for 1 year. The primary end point was the response rate (RR) to preoperative chemotherapy determined by central peer review according to the Response Evaluation Criteria in Solid Tumors version 1.0. The planned sample size was 50, with one-sided alpha of 10 %, power of 80 %, expected RR of 80 %, and threshold of 65 %. Results: Between July 2011 and May 2013, 53 patients were enrolled, of whom 52 were eligible. The clinical RR was 57.7 % [30/52, 80 % confidence interval 47.9-67.1 %, p = 0.89], and R0 resection was achieved in 84.6 % of patients (44/52). Common grade 3 or grade 4 adverse events during DCS therapy were leukocytopenia (18.9 %), neutropenia (39.6 %), and hyponatremia (15.1 %). The common grade 3 or grade 4 surgical morbidity was abdominal infection (10.2 %). The pathological RR was 50.0 % (26/52). Conclusions: Preoperative DCS therapy was feasible but did not show a sufficient RR. Preoperative cisplatin and S-1 therapy is still considered the tentative standard treatment for this population until survival results are known. [ABSTRACT FROM AUTHOR]

: Copyright of Gastric Cancer is the property of Springer Nature and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)

المؤلفون: Yokota, Tomoya, Ando, Nobutoshi, Igaki, Hiroyasu, Shinoda, Masayuki, Kato, Ken, Mizusawa, Junki, Katayama, Hiroshi, Nakamura, Kenichi, Fukuda, Haruhiko, Kitagawa, Yuko

المصدر: Oncology; Aug2015, Vol. 89 Issue 3, p143-151, 9p, 1 Diagram, 3 Charts, 2 Graphs

مصطلحات موضوعية: ANTINEOPLASTIC agents, ACADEMIC medical centers, BLOOD testing, COMBINATION drug therapy, CHI-squared test, CISPLATIN, CLINICAL trials, COMBINED modality therapy, CONFIDENCE intervals, ESOPHAGEAL tumors, FLUOROURACIL, MULTIVARIATE analysis, REGRESSION analysis, RESEARCH funding, RISK assessment, SQUAMOUS cell carcinoma, TUMOR classification, TREATMENT effectiveness, PROPORTIONAL hazards models, PATIENT selection, DATA analysis software, DESCRIPTIVE statistics, KAPLAN-Meier estimator, THERAPEUTICS, PROGNOSIS

مستخلص: Objective: Neoadjuvant chemotherapy with 5-fluorouracil plus cisplatin and subsequent esophagectomy with two- to three-field lymphadenectomy is a standard treatment for patients with clinical stage II/III squamous cell carcinoma (SCC) of the esophagus. This study investigates the prognostic factors for patients who received neoadjuvant chemotherapy. Methods: Of 164 patients assigned to receive neoadjuvant chemotherapy in the JCOG9907 trial, multivariate analyses were performed for 159 and 149 patients to evaluate the preoperative and the combined preoperative and postoperative prognostic factors, respectively. Results: The multivariate analyses using preoperative factors showed that clinical stage T3 [vs. cT1-2; hazard ratio (HR) 3.60, p = 0.0007] and serum albumin (Alb) <4.0 g/dl (vs. ≥4.0 g/dl; HR 2.29, p = 0.0005) were associated with a poor prognosis. Four independent prognostic factors were identified by multivariate analysis of both preoperative and postoperative factors: pathological curability B (pB; R0 with stage IV or pD < pN) or pC [microscopic or macroscopic residual tumor (R1/R2)] [vs. pA (R0); HR 1.93, p = 0.015], pathological stage N1 (vs. pN0; HR 3.86, p = 0.0012), cT3 (vs. cT1-2; HR 2.80, p = 0.0073), and serum Alb <4.0 g/dl (vs. ≥4.0 g/dl; HR 2.03, p = 0.0069). Conclusions: Preoperative cT stage, Alb, and postoperative pathological findings are independent prognostic factors for patients undergoing neoadjuvant chemotherapy for advanced thoracic esophageal SCC. This analysis may aid in stratification according to individual patient risk. © 2015 S. Karger AG, Basel [ABSTRACT FROM AUTHOR]

: Copyright of Oncology is the property of Karger AG and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)

المؤلفون: Katayama, Hiroshi¹, Wang, Jin¹, Treekitkarnmongkol, Warapen¹, Kawai, Hidehiko², Sasai, Kaori¹, Zhang, Hui¹, Wang, Hua³, Adams, Henry P.⁴, Jiang, Shoulei¹, Chakraborty, Sandip N.¹, Suzuki, Fumio², Arlinghaus, Ralph B.¹, Liu, Jinsong³, Mobley, James A.^5,6, Grizzle, William E.^6,7, Wang, Huamin³, Sen, Subrata¹ ssen@mdanderson.org

المصدر: Cancer Cell. Feb2012, Vol. 21 Issue 2, p196-211. 16p.

مصطلحات موضوعية: *AURORA kinases, *DNA damage, *APOPTOSIS, *GENE expression, *CISPLATIN, *TUMOR proteins, *MOLECULAR oncology

مستخلص: Summary: Elevated Aurora kinase-A expression is correlated with abrogation of DNA damage-induced apoptotic response and mitotic spindle assembly checkpoint (SAC) override in human tumor cells. We report that Aurora-A phosphorylation of p73 at serine235 abrogates its transactivation function and causes cytoplasmic sequestration in a complex with the chaperon protein mortalin. Aurora-A phosphorylated p73 also facilitates inactivation of SAC through dissociation of the MAD2-CDC20 complex in cells undergoing mitosis. Cells expressing phosphor-mimetic mutant (S235D) of p73 manifest altered growth properties, resistance to cisplatin- induced apoptosis, as well as premature dissociation of the MAD2-CDC20 complex, and accelerated mitotic exit with SAC override in the presence of spindle damage. Elevated cytoplasmic p73 in Aurora-A overexpressing primary human tumors corroborates the experimental findings. [Copyright &y& Elsevier]